{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T12:41:14Z","timestamp":1768567274825,"version":"3.49.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"2","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1007\/s40120-017-0084-6","type":"journal-article","created":{"date-parts":[[2017,11,8]],"date-time":"2017-11-08T08:50:05Z","timestamp":1510131005000},"page":"197-211","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Safety and Effectiveness of Natalizumab: First Report of Interim Results of Post-Marketing Surveillance in Japan"],"prefix":"10.1007","volume":"6","author":[{"given":"Takahiko","family":"Saida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazumasa","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryusuke","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruki","family":"Makioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukihiko","family":"Iizuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masakazu","family":"Hase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Ling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Torii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,11,8]]},"reference":[{"key":"84_CR1","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","volume":"354","author":"CH Polman","year":"2006","unstructured":"Polman CH, O\u2019Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354:899\u2013910.","journal-title":"N Engl J Med"},{"key":"84_CR2","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S1474-4422(09)70021-3","volume":"8","author":"E Havrdova","year":"2009","unstructured":"Havrdova E, Galetta S, Hutchinson M, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 2009;8:254\u201360.","journal-title":"Lancet Neurol"},{"key":"84_CR3","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa044396","volume":"354","author":"RA Rudick","year":"2006","unstructured":"Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354:911\u201323.","journal-title":"N Engl J Med"},{"key":"84_CR4","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1136\/jnnp-2013-306936","volume":"85","author":"H Butzkueven","year":"2014","unstructured":"Butzkueven H, Kappos L, Pellegrini F, et al. Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results. J Neurol Neurosurg Psychiatry. 2014;85:1190\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"84_CR5","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1056\/NEJMoa051782","volume":"353","author":"BK Kleinschmidt-DeMasters","year":"2005","unstructured":"Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med. 2005;353:369\u201374.","journal-title":"N Engl J Med"},{"key":"84_CR6","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1056\/NEJMoa051586","volume":"353","author":"G Assche Van","year":"2005","unstructured":"Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn\u2019s disease. N Engl J Med. 2005;353:362\u20138.","journal-title":"N Engl J Med"},{"key":"84_CR7","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1056\/NEJMoa051847","volume":"353","author":"A Langer-Gould","year":"2005","unstructured":"Langer-Gould A, Atlas SW, Green AJ, et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med. 2005;353:375\u201381.","journal-title":"N Engl J Med"},{"key":"84_CR8","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa054693","volume":"354","author":"TA Yousry","year":"2006","unstructured":"Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med. 2006;354:924\u201333.","journal-title":"N Engl J Med"},{"key":"84_CR9","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/ana.22606","volume":"70","author":"C Bozic","year":"2011","unstructured":"Bozic C, Richman S, Plavina T, et al. Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1. Ann Neurol. 2011;70:742\u201350.","journal-title":"Ann Neurol"},{"key":"84_CR10","unstructured":"Biogen Japan Ltd. Tysabri\u00ae package  insert (ver. 4). Tokyo: Biogen Japan Ltd; 2016 (in Japanese)."},{"key":"84_CR11","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","volume":"366","author":"G Bloomgren","year":"2012","unstructured":"Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366:1870\u201380.","journal-title":"N Engl J Med"},{"key":"84_CR12","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(08)70042-5","volume":"7","author":"GC Ebers","year":"2008","unstructured":"Ebers GC. Environmental factors and multiple sclerosis. Lancet Neurol. 2008;7:268\u201377.","journal-title":"Lancet Neurol"},{"key":"84_CR13","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.msard.2016.11.002","volume":"11","author":"T Saida","year":"2017","unstructured":"Saida T, Kira J, Kishida S, et al. Efficacy, safety, and pharmacokinetics of natalizumab in Japanese multiple sclerosis patients: a double-blind, randomized controlled trial and open-label pharmacokinetic study. Mult Scler Relat Disord. 2017;11:25\u201331.","journal-title":"Mult Scler Relat Disord"},{"key":"84_CR14","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s40120-016-0059-z","volume":"6","author":"T Saida","year":"2017","unstructured":"Saida T, Kira J-I, Kishida S, et al. Safety and efficacy of natalizumab in Japanese patients with relapsing-remitting multiple sclerosis: open-label extension study of a phase 2 trial. Neurol Ther. 2017;6:39\u201355.","journal-title":"Neurol Ther"},{"key":"84_CR15","doi-asserted-by":"crossref","first-page":"e48592","DOI":"10.1371\/journal.pone.0048592","volume":"7","author":"S Yoshimura","year":"2012","unstructured":"Yoshimura S, Isobe N, Yonekawa T, et al. Genetic and infectious profiles of Japanese multiple sclerosis patients. PLoS One. 2012;7:e48592.","journal-title":"PLoS One"},{"key":"84_CR16","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/gene.2011.25","volume":"12","author":"JP McElroy","year":"2011","unstructured":"McElroy JP, Isobe N, Gourraud PA, et al. SNP-based analysis of the HLA locus in Japanese multiple sclerosis patients. Genes Immun. 2011;12:523\u201330.","journal-title":"Genes Immun"},{"key":"84_CR17","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/WCO.0000000000000328","volume":"29","author":"H Ochi","year":"2016","unstructured":"Ochi H, Fujihara K. Demyelinating diseases in Asia. Curr Opin Neurol. 2016;29:222\u20138.","journal-title":"Curr Opin Neurol"},{"key":"84_CR18","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","volume":"82","author":"DK Sato","year":"2014","unstructured":"Sato DK, Callegaro D, Lana-Peixoto MA, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology. 2014;82:474\u201381.","journal-title":"Neurology"},{"key":"84_CR19","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1001\/archneurol.2011.216","volume":"69","author":"I Kleiter","year":"2012","unstructured":"Kleiter I, Hellwig K, Berthele A, et al. Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol. 2012;69:239\u201345.","journal-title":"Arch Neurol"},{"key":"84_CR20","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1212\/01.wnl.0000242629.66372.33","volume":"67","author":"JT Phillips","year":"2006","unstructured":"Phillips JT, O\u2019Connor PW, Havrdova E, et al. Infusion-related hypersensitivity reactions during natalizumab treatment. Neurology. 2006;67:1717\u20138.","journal-title":"Neurology"},{"key":"84_CR21","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1212\/WNL.0b013e31821e7c8a","volume":"76","author":"PW O\u2019Connor","year":"2011","unstructured":"O\u2019Connor PW, Goodman A, Kappos L, et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology. 2011;76:1858\u201365.","journal-title":"Neurology"},{"key":"84_CR22","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1001\/jamaneurol.2014.1200","volume":"71","author":"M Clerico","year":"2014","unstructured":"Clerico M, Schiavetti I, De Mercanti SF, et al. Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study). JAMA Neurol. 2014;71:954\u201360.","journal-title":"JAMA Neurol"},{"key":"84_CR23","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/ana.24286","volume":"76","author":"T Plavina","year":"2014","unstructured":"Plavina T, Subramanyam M, Bloomgren G, et al. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol. 2014;76:802\u201312.","journal-title":"Ann Neurol"},{"key":"84_CR24","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1177\/1352458513477925","volume":"19","author":"T Olsson","year":"2013","unstructured":"Olsson T, Achiron A, Alfredsson L, et al. Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort. Mult Scler. 2013;19:1533\u20138.","journal-title":"Mult Scler"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-017-0084-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,11,23]],"date-time":"2017-11-23T13:33:06Z","timestamp":1511443986000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40120-017-0084-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,8]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["84"],"URL":"https:\/\/doi.org\/10.1007\/s40120-017-0084-6","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,8]]}}}